Nasdaq · Healthcare

Arcturus Therapeutics Holdings Inc. (ARCT)

As-reported financials and recent SEC filings for Arcturus Therapeutics Holdings Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$82.0M

Net income

$-65.8M

Net margin

-80.2%

Diluted EPS

$-2.40

ROE

-30.7%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$82.0M	$152.3M	$166.8M	$206.0M	$12.4M
Gross profit	—	—	—	—	—
Operating income	$-76.3M	$-95.7M	$-78.2M	$12.2M	$-202.9M
Net income	$-65.8M	$-80.9M	$-29.7M	$9.3M	$-203.7M
Diluted EPS	$-2.40	$-3.00	$-1.12	$0.35	$-7.74

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-07-02

42026-06-15

42026-06-15

42026-06-15

42026-06-15

42026-06-15

42026-06-15

42026-06-15

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on ARCT

Search Arcturus Therapeutics Holdings Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.